iANTHUS CAPITAL HOLDINGS (ITHUF) Non-Current Debt (2020 - 2026)
iANTHUS CAPITAL HOLDINGS's (ITHUF) quarterly Non-Current Debt came in at $198.7 million in Q1 2026, up 16.07% year-on-year from $171.2 million in Q1 2025, and up 2.45% quarter-over-quarter from $194.0 million in Q4 2025.
iANTHUS CAPITAL HOLDINGS (ITHUF) Non-Current Debt (2020 - 2026) Analysis & Trends
iANTHUS CAPITAL HOLDINGS has disclosed Non-Current Debt across 7 years of filings, most recently posting $198.7 million for Q1 2026.
- Non-Current Debt for Q1 2026 came in at $198.7 million, up 16.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $198.7 million (up 16.07% YoY), and the FY2025 annual result was $194.0 million, up 6.43% from the prior year.
- Non-Current Debt came in at $198.7 million for Q1 2026 at iANTHUS CAPITAL HOLDINGS, up from $194.0 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $198.7 million in Q1 2026 to a low of $16.3 million in Q1 2022.
- The 5-year median for Non-Current Debt is $168.4 million (2024), against an average of $154.7 million.
- Across the five-year window, Non-Current Debt slumped 36.16% in 2022 and surged 740.74% in 2023, its largest moves.
- iANTHUS CAPITAL HOLDINGS's Non-Current Debt stood at $147.3 million in 2022, then increased by 12.2% to $165.2 million in 2023, then grew by 10.31% to $182.3 million in 2024, then advanced by 6.43% to $194.0 million in 2025, then grew by 2.45% to $198.7 million in 2026.
- The last three Non-Current Debt figures came in at $198.7 million (Q1 2026), $194.0 million (Q4 2025), and $180.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 14.02 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 9.05 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 3.92 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.48 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | - |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 569.60 Mn |
| 10 | iANTHUS CAPITAL HOLDINGS | - | - | 15.92 Mn | 198.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198.73 Mn |
| Mar 31, 2026 | 198.73 Mn |
| Dec 31, 2025 | 193.99 Mn |
| Dec 31, 2025 | 193.99 Mn |
| Sep 30, 2025 | 180.72 Mn |
| Sep 30, 2025 | 180.72 Mn |
| Jun 30, 2025 | 175.90 Mn |
| Jun 30, 2025 | 175.90 Mn |
| Mar 31, 2025 | 171.22 Mn |
| Mar 31, 2025 | 171.22 Mn |
| Dec 31, 2024 | 182.26 Mn |
| Dec 31, 2024 | 182.26 Mn |
| Sep 30, 2024 | 177.53 Mn |
| Sep 30, 2024 | 177.53 Mn |
| Jun 30, 2024 | 172.88 Mn |
| Jun 30, 2024 | 172.88 Mn |
| Mar 31, 2024 | 168.36 Mn |
| Mar 31, 2024 | 168.36 Mn |
| Dec 31, 2023 | 165.22 Mn |
| Dec 31, 2023 | 165.22 Mn |